Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > H. C. Wainwright 22nd Annual Global Investment Conference

<< Previous

Bullboard Posts

Next >>

Comment by aldo451on Sep 17, 2020 10:03am

115 Views

Post# 31573686

RE:RE:RE:RE:RE:RE:RE:H. C. Wainwright 22nd Annual Global Investment Conference

Hi Bio,

I was being sarcastic with the pinheads on this board.

Unlike some here who claim to know what is going on internally, their Master plan to screw us all over and the faith of the company, I don’t, and I have been following this company for a long, long time.

However, two years and $M’s later, they have finally submitted the BLA and are forging ahead with or without a partner; “US and foreign market access strategy under development”. Once approved or perhaps even after they receive the “new action date” from the FDA (which should arrive any day), signing a partner will be easier and more lucrative for LMNL, but as someone else mentioned, why partner at that point and they may elect to go at it alone

As for the cash situation, I think that they will go to market (public offering) hopefully after approval (higher share price) with the support of Thomvest until they get there.